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ORIGINAL RESEARCH REPORT

Efﬁcacy of Allogeneic Hematopoietic Cell
Transplantation in Patients With Chronic Phase CML
Resistant or Intolerant to Tyrosine Kinase Inhibitors
Farah Yassine a, Tea Reljic b, Muhamad Alhaj Moustafa a, Madiha Iqbal a,
Hemant S. Murthy a, Ambuj Kumar b, Mohamed A. Kharfan-Dabaja a,*
a

Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program, Mayo Clinic Florida,
Jacksonville, FL, USA
b
Research Methods and Biostatistics Core, Morsani College of Medicine, University of South Florida, Tampa, FL, USA

Abstract
Approximately 15e20% of chronic myeloid leukemia (CML) patients fail tyrosine kinase inhibitor (TKI) therapy
secondary to resistance or intolerance. In the pre-TKI era, front-line allogeneic hematopoietic cell transplantation (alloHCT) represented the standard approach for patients with chronic phase-CML (CP-CML) who were deemed ﬁt to
tolerate the procedure and had a human leukocyte antigen compatible donor available. Currently, CP-CML patients are
eligible for allo-HCT only if they fail more than one TKI and/or are intolerant to the drug. We performed a systematic
review/meta-analysis of the available literature to assess the evidence regarding allo-HCT efﬁcacy in CP-CML patients.
Data from eligible studies were extracted in relation to beneﬁts (overall survival [OS], progression-free survival, diseasefree survival [DFS], complete remission [CR], and molecular response [MR]) and harms (nonrelapse mortality [NRM],
relapse, and acute and chronic graft-versus-host disease), and stratiﬁed by age into adult and pediatric groups. For adult
allo-HCT recipients, the pooled OS, DFS, CR and, MR were 84% [95% conﬁdence interval (CI) 59e99%], 66% (95% CI
59e73%), 56% (95% CI 30e80%), and 88% (95% CI 62e98%), respectively. Pooled NRM and relapse were 20% (95% CI
15e26%) and 19% (95% CI 10e28%), respectively. For the pediatric group, the OS rate was reported in one study and was
91% (95% CI 72e99%). Our results suggest that allo-HCT is an effective treatment for TKI-resistant or TKI-intolerant CPCML. Post-transplant strategies are still needed to further mitigate the risk of relapse.
Keywords: Allogeneic hematopoietic cell transplantation, Chronic myeloid leukemia, Chronic phase, Intolerance,
Resistance, Tyrosine kinase inhibitors

1. Introduction

I

ncorporation of tyrosine kinase inhibitors (TKIs)
into the treatment algorithm of chronic myeloid
leukemia (CML) in chronic phase (CP) marked the
beginning of a new era that largely replaced the use
of allogeneic hematopoietic cell transplantation
(allo-HCT) in the front-line setting [1]. Two decades
later, allo-HCT, albeit relegated to a salvage therapy
following TKI resistance or intolerance, remains a
reasonable option for CP-CML. It is estimated that
approximately 15e20% of patients would fail TKI

therapy secondary to resistance or intolerance [2].
The European Leukemia Network recommends
allo-HCT to be considered for patients who are
resistant or intolerant to at least one of the secondgeneration TKIs [3].
Conducted in the TKI era, the German CML study
IV reported outcomes of 84 patients who underwent
allo-HCT after imatinib failure or due to advanced
disease: the 3-year survival for 56 patients who were
allografted in CP was 91%, whereas it was 59% for
those in advanced phase. Nonrelapse mortality
(NRM) was estimated at 8% for patients who received
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an allo-HCT in CP compared with 18% for those
transplanted at later stages [4]. Another study from a
Swedish registry reported outcomes of 118 patients
(47.5% in CP) who underwent allo-HCT for CML
between 2002 and 2017. In this study, TKI resistance
was the most common indication for allo-HCT
(62.5%). The 5-year overall survival (OS) was 96.2%,
70.1%, and 36.9% for patients in CP1, CP2/>CP2, and
advanced phase/blast phase, respectively [5].
In the absence of a randomized controlled study
for TKI-resistant and/or TKI-intolerant CP-CML
that compares allo-HCT with other available therapies, we perform a systematic review/meta-analysis
(SR/MA) of the available literature to assess the totality of evidence regarding the efﬁcacy of allo-HCT
in patients with TKI-resistant CP-CML.

2. Methods
2.1. Search and selection of eligible studies
We followed the recommendations by the
Cochrane Collaboration for the minimum number of
databases to be searched (i.e. n ¼ 2). According to a
predeﬁned protocol, a comprehensive search of the
published medical literature was undertaken using
two major databases, namely, PubMed/MEDLINE
and Embase on January 24, 2020 (Appendix 1). In
addition, we performed a manual search of cited
references from relevant narrative review articles to
identify additional eligible studies. We did not apply
any search limits based on country of origin, date of
study conduct, or study setting (prospective, retrospective from a single center or multiple centers, or
registry data), but excluded studies that were not in
English or only reported in abstract form.
Eligibility for inclusion in this SR/MA required
that studies must have enrolled 10 or more patients
who received an allo-HCT for treating CP-CML that
was either TKI resistant or intolerant. Selection of
included studies was undertaken by two authors
(F.Y. and M.A.K-D). Possible disagreements were
resolved by consensus majority in consultation with
two separate coauthors (T.R. and A.K.).
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host disease), and the risk of bias. All outcomes
were stratiﬁed by age group into adults (median age
and lower limit of age range  18 years) and pediatrics (deﬁned as median age and upper limit of age
range < 18 years). Studies which had an overlap of
these age cut-offs were grouped under the label of
mixed/unclear population.
The methodologic quality of eligible studies was
assessed using the NewcastleeOttawa Scale modiﬁed for single-arm cohort studies [6].
2.3. Statistical analysis
In this SR/MA, we calculated proportions for each
speciﬁc outcome of interest. For the MA, the proportions were transformed into quantities according
to the FreemaneTukey variant of the arcsine square
root-transformed proportion [7,8]. The pooled proportion was calculated as the back-transformation of
the weighted mean of the transformed proportions
using the random-effects model proposed by DerSimonian and Laird [7], which was used to pool data
from studies with similar deﬁnitions pertaining to
study design, study patients, and allo-HCT outcomes. All results are reported as rates with their
corresponding 95% conﬁdence intervals (CIs).
2.4. Analysis of heterogeneity
For pooled outcomes with data from four or more
studies, we assessed heterogeneity among the
studies included in this SR/MA using the I2 statistic
as described by Higgins et al. [9]. Moderate heterogeneity was deﬁned as I2 > 30%, and high heterogeneity was deﬁned as I2 > 60%. All analyses
reported in this SR/MA were performed by Stata
version 16 software (StataCorp LLC, College Station,
TX, USA) and the MetapropOne software package
(StataCorp LLC, College Station, TX, USA) [10]. The
review is reported in accordance with PRISMA
guidelines [11].

3. Results
3.1. Search results

2.2. Data collection
All authors extracted data from included studies
using a standardized data collection form. We
collected data on study and participant characteristics, clinical outcomes based on beneﬁts ([OS],
progression-free survival [PFS], disease-free survival [DFS], complete remission [CR], and molecular
response [MR]) and harms (NRM, relapse, and
acute [aGVHD] and chronic [cGVHD] graft-versus-

Our search strategy (Appendix 1) identiﬁed a total
of 1308 studies. Only nine studies (n ¼ 439 patients)
met our inclusion criteria [4,12e19]. Stratiﬁcation by
age group yielded three studies (n ¼ 200 patients) in
the adult, one study (n ¼ 28 patients) in the pediatric, and ﬁve studies (n ¼ 211 patients) in the mixed
population. The three most common reasons for
exclusion were (a) not a clinical study, (b) not CML
diagnosis, and (c) not allo-HCT (Fig. 1).
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Fig. 1. Study selection ﬂow diagram. Note. CP ¼ chronic phase; allo-HCT ¼ allogeneic hematopoietic cell transplantation; TKI ¼ tyrosine kinase
inhibitor.

3.2. Characteristics of included studies
Table 1 summarizes the characteristics of the
studies included in this SR/MA.
3.3. Assessment of methodological quality of
selected studies
Table 2 summarizes the methodologic quality and
risk of bias of the studies included in this SR/MA.
Three studies represented multiple institution data
[4,15,16] and three were registry studies [14,18,19].
In brief, the majority of the included studies were
classiﬁed as low/relatively low risk in terms of selection bias (for including a representative sample,
ascertainment of exposure, and baseline diagnosis)
and outcome bias (for assessment methods and
adequate follow-up).

CI 59e99%). Heterogeneity was nonassessable
(Fig. 2).
3.4.1.2. Pediatric. OS was reported in one study
(n ¼ 23) [15]. The OS rate was 91% (95% CI 72e99%;
Fig. 2).
3.4.1.3. Mixed/unclear population. OS was reported in
four studies (n ¼ 164) [4,17e19]. The pooled OS was
76% (95% CI 56e92%). Heterogeneity was high
(I2 ¼ 86.4%, p < .001; Fig. 2).
3.4.2. PFS
3.4.2.1. Mixed/unclear population. The PFS rate was
reported in one study (n ¼ 11) [17] and it was 82%
(95% CI 48e98%; Appendix 1, Figure a).
3.4.3. DFS

3.4.1. OS

3.4.3.1. Adult. The DFS rate was reported in three
studies (n ¼ 186) [12e14]. The pooled DFS rate was
66% (95% CI 59e73%). Heterogeneity was nonassessable (Appendix 1, Figure b).

3.4.1.1. Adult. OS was reported in three studies
(n ¼ 187) [12e14]. The pooled OS rate was 84% (95%

3.4.3.2. Mixed/unclear population. The DFS rate was
reported in two studies (n ¼ 97) [16,18]. The pooled

3.4. Outcomes
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Table 1. Post-transplant outcomes of eligible studies.
Study

Study
type

N1

N2

Median
age (range),
years

OS, %
PFS, %
DFS, %

CR, %
MR, %

NRM, %

Relapse, %

aGVHD, %
cGVHD, %

Single
center

47

16

44 (19e63)

CR: 56
MR: 88

19 (2 y)

25

NE

Nair et al. [13]

Single
center

51

17

45 (22e61)

NE

20 (1e5 y)

29
(1e5 years)

NE

Kondo et al. [14]

TRUMP
registry

237

154

42 (20e67)

OS: 75 (2 y)
PFS: NE
DFS: 63
OS: 100 (8 y)
PFS: NE
DFS: 71 (8 y)
OS: 70 (2 y)
PFS: NE
DFS: 65 (2 y)

NE

21 (2 y)

16
(2 years)

NE

Pediatric
Suttorp et al. [15]

Multicenter

28

23

13.2 (1.3e18)

OS: 91 (5 y)
PFS: NE
DFS: NE

NE

NE

NE

NE

Mixed/unclear
Bornh€
auser et al. [16]

Multicenter

61

47

45 (15e64)

NE

49 (100 d
to 1 y)

26
(18 months)

NE

Perz et al. [17]

Single
center

37

19

31 (16e55)

NE

12 (100 d)

NE

NE

Saussele et al. [4]

Multicenter

1,242

37

38 (16e56)

CR: NE
MR: 89

NE

NE

aGVHD: 68
cGVHD: 35

Lee et al. [18]

CIBMTR
registry

1,309

50

33 (14e54)

NE

NE

28
(4 years)

aGVHD: 46
cGVHD: 63

Kruger et al. [19]

ABMTR
registry

80

58

40 (17e63)

OS: NE
PFS: NE
DFS: 34 (18 mo)
OS: 68
PFS: 82
DFS: NE
Median
follow-up: 203 d
OS: 95 (3 y)
PFS: NE
DFS: NE
OS: 80 (4 y)
PFS: NE
DFS: 60 (4 y)
OS: 55 (5 y)
PFS: NE
DFS: NE

NE

NE

NE

NE

Adults
Jabbour et al. [12]

Note. ABMTR ¼ Australasian Bone Marrow Transplant Recipient; aGVHD ¼ acute graft-versus-host disease; cGVHD ¼ chronic graftversus-host disease; CIBMTR ¼ The Center for International Blood & Marrow Transplant Research; CML ¼ chronic myeloid leukemia;
CR ¼ complete remission; d ¼ day; DFS ¼ disease-free survival; F/U ¼ follow-up; mo ¼ month; MR ¼ molecular response; N1 ¼ number
of patients enrolled in the study; N2 ¼ number of patients included in the analysis; NE ¼ non-extractable data; NRM ¼ non-relapse
mortality; OS ¼ overall survival; PFS ¼ progression-free survival; TRUMP ¼ Transplant Registry Uniﬁed Management Program;
y ¼ year.

Table 2. Risk of bias in included studies.
Study

Adults
Jabbour et al. [12]
Nair et al. [13]
Kondo et al. [14]
Pediatric
Suttorp et al. [15]
Mixed/unclear
Bornh€
auser et al. [16]
Perz et al. [17]
Saussele et al. [4]
Lee et al. [18]
Kruger et al. [19]

Representativeness Ascertainment
of the patient cohort of exposure

Demonstration that the Assessment Length
outcome of interest was of outcome of follow-up
not present at the
start of study

Adequacy
of follow-up

Low risk
Unclear/high risk
Low risk

Low risk
Low risk
Low risk

Low risk
Low risk
Low risk

Low risk
Low risk
Low risk

Low risk
Low risk
Low risk

Low risk
Low risk
Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk

Low risk
Unclear/high risk
Low risk
Unclear/high risk
Unclear/high risk

Low risk
Low risk
Low risk
Low risk
Unclear/high risk Low risk
Low risk
Low risk
Low risk
Low risk

Low
Low
Low
Low
Low

Unclear/high risk Low risk
Unclear/high risk Low risk
Low risk
Low risk
Low risk
Low risk
Low risk
Low risk

risk
risk
risk
risk
risk
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Fig. 2. Overall survival (OS). Note. CI ¼ conﬁdence interval; ES ¼ effect size.

DFS was 47% (95% CI 37e57%; Appendix 1,
Figure b).

(95% CI 15e26%). Heterogeneity was nonassessable
(Fig. 3).

3.4.4. CR

3.4.6.2. Mixed/unclear population. NRM was reported
in two studies (n ¼ 97) [16,18]. The pooled NRM was
28% (95% CI 19e38%; Fig. 3).

3.4.4.1. Adult. The CR rate was reported in one study
(n ¼ 16) [12] and was 56% (95% CI 30e80%; Appendix 1, Figure c).
3.4.5. MR

3.4.7. Relapse

3.4.5.1. Adult. The MR rate was reported in one
study (n ¼ 16) [12] and was 88% (95% CI 62e98%;
Appendix 1, Figure d).

3.4.7.1. Adult. Relapse was reported in three studies
(n ¼ 187) [12e14]. The pooled relapse rate was 19%
(95% CI 10e28%). Heterogeneity was nonassessable
(Fig. 4).

3.4.5.2. Mixed/unclear population. The MR rate was
reported in one study (n ¼ 28) [4] and was 89% (95%
CI 72e98%; Appendix 1, Figure d).

3.4.7.2. Mixed/unclear population. Relapse was reported in two studies (n ¼ 97) [16,18]. The pooled
relapse was 27% (95% CI 18e36%; Fig. 4).

3.4.6. NRM

3.4.8. aGVHD

3.4.6.1. Adult. NRM was reported in three studies
(n ¼ 199) [12e14]. The pooled NRM rate was 20%

3.4.8.1. Mixed/unclear population. aGVHD was reported in two studies (n ¼ 87) [4,18]. The pooled

HEMATOLOGY/ONCOLOGY AND STEM CELL THERAPY 2022;15:36e43
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Fig. 3. Nonrelapse mortality (NRM). Note. CI ¼ conﬁdence interval; ES ¼ effect size.

aGVHD was 46% (95% CI 35e56%; Appendix 1,
Figure e).
3.4.9. cGVHD
3.4.9.1. Mixed/unclear population. cGVHD was reported in two studies (n ¼ 83) [4,18]. The pooled
cGVHD was 51% (95% CI 40e61%; Appendix 1,
Figure f).

4. Discussion
In the pre-TKI era, front-line allo-HCT represented the standard approach for patients with CPCML who were deemed ﬁt to tolerate the procedure
and had a human leukocyte antigen compatible
donor available. Following the emergence of imatinib mesylate, and later on newer generations of
TKIs, the role of allo-HCT in CP-CML was relegated
to later stages of the disease owing to both the high
response rates and long duration of remission
following TKI therapies [1,20e22]. Nowadays, patients with CP-CML are considered eligible for alloHCT only if they fail to respond to more than one
TKI and/or if they are unable to tolerate the drug.

This is not the case for patients with accelerated or
blastic phases of the disease for which allo-HCT
ought to be offered as front-line consolidation.
Results of this SR/MA show that allo-HCT yields
encouraging pooled OS rates of 84% in adults and
91% in the pediatric age group. These results are
noteworthy when considering that refractoriness to
TKIs probably represents a more aggressive disease
when compared with CP-CML that used to be
allografted in the past after demonstrating responses to inferior therapies such as interferon [23].
The effectiveness of allo-HCT highlights the need
for an early referral to a transplant center, particularly in the subgroup of CML patients with TKI
resistance conferred by acquired kinase domain
mutations.
Pertaining to harms, results of our SR/MA highlight a pooled NRM and relapse rates of 20% and
19%, respectively, in the adult age group. This emphasizes the need to develop better selection criteria
to reduce the NRM risk, and to implement posttransplant strategies that could help further mitigate
the risk of relapse. Early intervention in patients
with residual disease using donor lymphocyte infusion(s) and/or TKIs represents reasonable
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Fig. 4. Relapse. Note. CI ¼ conﬁdence interval; ES ¼ effect size.

approaches in this setting considering the proven
graft-versus-leukemia efﬁcacy of donor lymphocyte
infusion(s) in CML [24].
A major limitation of our study is the fact that
outcomes based on regimen intensity were not
extractable, as data were reported in aggregates
rather than segregated into myeloablative versus
reduced intensity regimens. Another limitation of
our analysis is that we could not analyze the outcomes separately for patients allografted for TKI
resistance versus those who received the procedure
for TKI intolerance. Intuitively, the latter may
represent a different disease biology for which
resistance may have not been conﬁrmed. Moreover,
considering the retrospective nature of most studies,
it is plausible that some may have an overlap of
patients. This could be the case of patients reported
in single-institution studies and in registry-based
data. Finally, we acknowledge a limitation of not
including studies published in abstract form only in
our SR and MA. While including abstracts is recommended, a recently published scoping review of
comparisons between abstracts and full reports in
primary biomedical research showed that abstracts
are frequently inconsistent with full reports [25].
Besides, our search only identiﬁed one eligible
study in the pediatric age group.

Notwithstanding aforementioned limitations, our
MA supports the need to develop future
studies assessing novel maintenance/consolidation
strategies to further reduce relapse following alloHCT.
In conclusion, our results suggest that allo-HCT is
an effective treatment strategy for CML patients
who are resistant or intolerant to TKIs.
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